このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

HER2の低発現を伴う局所進行性または転移性乳がんの治療のためのRC48-ADCの研究

2026年9月20日 更新者:RemeGen Co., Ltd.

HER2低発現の局所進行性または転移性乳がんの治療に対するRC48-ADCの有効性と安全性を評価する無作為化、対照、多施設共同第III相臨床試験

This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ,previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.

調査の概要

詳細な説明

This study is a multi-center, randomized, open, parallel control to evaluate the effectiveness and safety of Phase III clinical trials of the efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody-Monomethyl auristatin E (MMAE) conjugate for the treatment of locally advanced or metastatic breast cancer the study.The low expression of HER2 is defined as: the immunohistochemistry (IHC) confirmed by the central laboratory detects the expression of HER2 protein as IHC 2+ and the fluorescence in situ hybridization (FISH) detection has no amplification.

研究の種類

介入

入学 (推定)

366

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Binghe Xu, M.D.
  • 電話番号:010-87788826
  • メール:bhxu@hotmail.com

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100021
        • 募集
        • Oncology Hospital, Chinese Academy of Medical Sciences
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~70年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Voluntarily agree to participate in the study and sign the informed consent;
  • Subjects aged 18-70 years (including 18 years and 70 years) and not reaching the 71st birthday were all considered to be ≤70 years old;
  • Expected survival ≥12 weeks;
  • Eastern Cooperative Oncology Group(ECOG) physical condition 0 or 1;
  • For female subjects of child-bearing age women agreed to study during treatment and experimental subjects within 6 months after the end of the treatment period using an approved by the medical contraception (e.g. intrauterine device, the pill or condoms), before the study drug delivery within 7 days of pregnancy blood test must be negative (sterilization surgery or age 60 or more subjects can choose no pregnancy blood test), and must be an lactation. For male subjects: should be sterilized surgically, or agree to use a medically approved contraceptive method during the study period and for 6 months after the end of the treatment period. Control subjects after the end of the treatment period according to the choice of control drugs to determine the length of contraception.
  • Able to understand the study requirements and be willing and able to follow the study and follow-up procedures.
  • Bone marrow function:

hemoglobin ≥9g/dL; absolute neutrophil count ≥1.5×109/L; white blood cell count ≥3.0×109/L platelet ≥100 ×109/L;

  • Liver function (according to the normal value of the clinical trial center) :

serum total bilirubin ≤1.5 times the upper limit of normal value (ULN); alanine aminotransferase (ALT), aspartate aminotransferase(AST) and Alkaline phosphatase(ALP) were ≤2.5 × ULN in the absence of liver metastasis, and ALT, AST and Alkaline phosphatase(ALP) were ≤5 × ULN in the presence of liver metastasis

  • Renal function (according to the normal value of the clinical trial center) :

serum creatinine ≤1.5×ULN, or calculated by Cockcroft-Gault formula, the creatinine clearance rate (CrCl) ≥60 mL/min;

  • Cardiac function:

American New York college of cardiology (NYHA) grade < 3; left ventricular ejection fraction ≥50%;

  • Breast cancer subjects diagnosed by histology and / or cytology are currently at a locally advanced or metastatic stage and cannot be radically removed;
  • The low expression of HER2 confirmed by the IHC and FISH results of the central laboratory (defined as: IHC 2+ and no amplification of FISH); the subject can provide a specimen of the primary or metastatic tumor site (paraffin wax) for HER2 detection Block, paraffin-embedded section or fresh tissue section can be used);
  • Previous use of anthracycline drugs;
  • Received 1 or 2 systemic chemotherapy treatments after relapse / metastasis. Subjects who relapsed during adjuvant chemotherapy or within 12 months after the end of adjuvant chemotherapy were considered to have failed first-line chemotherapy after relapse / metastasis.
  • Hormone receptors are negative or positive. Hormone receptor-positive subjects need to progress after receiving endocrine therapy after relapse / metastasis or relapse after less than 2 years. Patients who are not suitable for endocrine therapy can be included in this study after undergoing chemotherapy treatment (first-line or second-line);
  • The imaging evidence confirmed by the investigator that the tumor disease progressed during or after the most recent treatment is required;
  • There has been no diagnosis of HER2 positive (HER2 IHC 3+ or FISH amplification)
  • Have not used drugs targeting HER2 (including antibodies, small molecule Tyrosine kinase inhibitor(TKIs) and antibody drug conjugates).
  • According to the RECIST 1.1 standard, there is at least one measurable lesion.

Exclusion Criteria:

  • Received chemotherapy within 4 weeks before the start of study administration (treatment with nitrosourea and mitomycin C within 6 weeks, oral fluorouracil within 2 weeks), radiotherapy (palliative for bone metastases Local radiotherapy is within 2 weeks before study administration), immunotherapy; received endocrine therapy for breast cancer within 2 weeks before study administration;
  • The research drug was used within 4 weeks before the start of study administration;
  • Have undergone major surgery within 4 weeks before the start of study administration;
  • Have received a live vaccine within 4 weeks before the start of study administration or plan to receive any vaccine during the study period;
  • Serious cardiovascular and cerebrovascular events occurred within 12 months, including but not limited to unstable angina, myocardial infarction, cerebral hemorrhage, and cerebral infarction (except for asymptomatic and untreated lacunar infarction);
  • Those who are suffering from heart disease are not suitable for enrollment, including but not limited to arrhythmia and heart failure requiring medical treatment or accompanied by symptoms;
  • There are other lung diseases requiring treatment or serious, including but not limited to active pulmonary tuberculosis, interstitial lung disease, etc ;
  • Suffering from active infection requiring systemic treatment;
  • Have active autoimmune diseases (such as the use of corticosteroids or immunosuppressive drugs, etc.) that require systemic treatment within the past 2 years, allowing related alternative treatments (such as thyroxine, insulin, or the physiology of adrenal or pituitary insufficiency Corticosteroid replacement therapy);
  • The toxicity of the previous anti-tumor therapy has not been restored to the 0 to 1 level defined by CTCAE version 5.0, of which the neurotoxicity has not been restored to 0; except for hair loss, pigmentation or other researches that do not increase the risk of medication Happening;
  • Have a clear past or current history of neurological or mental disorders, including epilepsy or dementia;
  • According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the clinical study;
  • Positive HIV test results; patients with active hepatitis B or C (HBsAg positive and hepatitis B virus(HBV) DNA titers above the upper limit of normal; Hepatitis C Virus Antibody(HCVAb) positive hepatitis C virus (HCV) RNA titers above the upper limit of normal);
  • There is a third interstitial fluid that cannot be controlled by drainage or other methods (including a large amount of pleural effusion or ascites);
  • Known hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or similar drugs;
  • Subjects who are not suitable for using any of the alternative control drugs;
  • The presence of brain metastases and / or cancerous meningitis;
  • Have other malignant tumors within 5 years before signing the informed consent form (except for non-melanoma skin cancer, cervical carcinoma in situ or other tumors that have been effectively treated, except malignant tumors that are considered cured);
  • Subjects who are estimated to be inadequate for patients to participate in this clinical study or other factors that the investigator believes are inappropriate to participate in this study;

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:RC48-ADC

RC48-ADC common name:Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection Dosage form:Lyophilized powder injection specification:60 mg / piece Medication plan:Every 2 weeks Expiration date:18 months HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.

RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks

他の名前:
  • RC48
アクティブコンパレータ:Physician's Choice

Physician's Choice:

HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.

Physician's choice from the following options:

Paclitaxel Injection Docetaxel Injection Vinorelbine Tartrate Injection Capecitabine Tablets

Administered according to label, as one option for Physician's Choice (determined before randomization)

他の名前:
  • タキソール

Administered according to label, as one option for Physician's Choice (determined before randomization)

他の名前:
  • タキソテール

Administered according to label, as one option for Physician's Choice (determined before randomization)

他の名前:
  • ナベルバイン

Administered according to label, as one option for Physician's Choice (determined before randomization)

他の名前:
  • ゼローダ

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Progression-free survival (PFS), evaluated by an independent efficacy evaluation committee
時間枠:within approximately 3 years

Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.

within approximately 3 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Progression-free survival (PFS), evaluated by the investigator
時間枠:within approximately 3 years

Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.

within approximately 3 years
Objective remission rate (ORR)
時間枠:within approximately 3 years

The objective response rate will be mainly analyzed by the independent efficacy evaluation committee according to the RECIST 1.1 standard tumor evaluation (the evaluation by the investigator will also be performed).

within approximately 3 years
Duration of relief (DOR)
時間枠:within approximately 3 years

DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death

within approximately 3 years
Disease control rate (DCR)
時間枠:within approximately 3 years

Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study.

within approximately 3 years
Tumor progression time (TTP)
時間枠:within approximately 3 years

Time to disease progression (TTP) refers to the time from the random date to the first disease progression (calculated by the event that occurred first). Disease progression will be evaluated by the investigator according to the RECIST 1.1 standard (investigator and Independent Review Committee(IRC) evaluation).

within approximately 3 years
Overall survival (OS)
時間枠:within approximately 3 years

Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject.

within approximately 3 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Yu Jiang、West China Hospital
  • 主任研究者:Binghe Xu、Oncology Hospital, Chinese Academy of Medical Sciences
  • 主任研究者:Wei Li、Jilin University First Hospital
  • 主任研究者:Xiaojia Wang、Zhejiang Cancer Hospital
  • 主任研究者:Ying Wang、Sun Yat-sen University Cancer Prevention and Control Center
  • 主任研究者:Ning Liao、Guangdong Provincial People's Hospital
  • 主任研究者:Haibo Wang、Qingdao University Hospital
  • 主任研究者:Quchang Ouyang、Hunan Cancer Hospital
  • 主任研究者:Yueyin Pan、Anhui Provincial Hospital
  • 主任研究者:Yingying Du、The First Affiliated Hospital of Anhui Medical University
  • 主任研究者:Jin Yang、The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine
  • 主任研究者:Xiuwen Wang、Qilu Hospital of Shandong University
  • 主任研究者:Huihua Xiong、Tongji Hospital
  • 主任研究者:Xinhong Wu、Hubei Cancer Hospital
  • 主任研究者:Weimin Xie、Cancer Hospital Affiliated to Guangxi Medical University
  • 主任研究者:Xin Zhou、Chongqing University Cancer Hospital
  • 主任研究者:Li Ran、Cancer Hospital of Guizhou Province
  • 主任研究者:Yu Wang、Shanxi Province Cancer Hospital
  • 主任研究者:Jinnan Gao、Bethune Hospital of Shanxi Province
  • 主任研究者:Jingfen Wang、Linyi Cancer Hospital
  • 主任研究者:Xianhe Xie、First Affiliated Hospital of Fujian Medical University
  • 主任研究者:Ru Zeng、The First Affiliated Hospital of Xiamen University
  • 主任研究者:Airong Wang、Weihai Municipal Hospital
  • 主任研究者:Zhengqiu Zhu、The Affiliated Hospital of Xuzhou Medical University
  • 主任研究者:Sanyuan Sun、Xuzhou Central Hospital
  • 主任研究者:Qingshan Li、Affiliated Hospital of Chengde Medical College
  • 主任研究者:Aimin Zang、Affiliated Hospital of Hebei University
  • 主任研究者:Liuzhong Yang、The First Affiliated Hospital of Xinxiang Medical College
  • 主任研究者:Meili Sun、Jinan Central Hospital
  • 主任研究者:Liang Li、Zibo Central Hospital
  • 主任研究者:Guohua Yu、Weifang People's Hospital
  • 主任研究者:Xujuan Wang、Neijiang Second People's Hospital
  • 主任研究者:Ying Wang、Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • 主任研究者:Ying Cheng、Jilin Provincial Tumor Hospital
  • 主任研究者:Jifeng Feng、Jiangsu Cancer Institute & Hospital
  • 主任研究者:Tao Sun、Liaoning Cancer Hospital & Institute
  • 主任研究者:Yuee Teng、First Hospital of China Medical University
  • 主任研究者:Shu Wang、Peking University People's Hospital
  • 主任研究者:Min Yan、Henan Cancer Hospital
  • 主任研究者:Changlu Hu、Anhui Provincial Cancer Hospital
  • 主任研究者:Zhongsheng Tong、Tianjin Cancer Hospital Airport Hospital
  • 主任研究者:Lihua Song、Shandong Cancer Hospital and Institute
  • 主任研究者:Yunjiang Liu、Hebei Medical University Fourth Hospital
  • 主任研究者:Jing Cheng、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • 主任研究者:Peng Shen、First Affiliated Hospital of Zhejiang University
  • 主任研究者:Liangming Zhang、Yantai Yuhuangding Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2020年9月29日

一次修了 (推定)

2027年12月31日

研究の完了 (推定)

2027年12月31日

試験登録日

最初に提出

2020年4月30日

QC基準を満たした最初の提出物

2020年5月19日

最初の投稿 (実際)

2020年5月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月23日

QC基準を満たした最後の更新が送信されました

2026年9月20日

最終確認日

2026年9月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する